During last decade, the introduction of microarray technology has had a profound impact on gene expression and molecular Biology research. Instead of measuring the expression of one or a few genes, microarrays can query the expression level of thousands of genes simultaneously, providing an extremely powerful tool for the characterization of processes as diverse as development, disease detection, drug effects and pathogen response. Data mining from microarray analysis is already having a great impact in both basic and applied research, and predictions indicate that array technology will revolutionize our approach to medicine.
Microarray is a rapid and cost-effective means of generating sequence data which help scientists to detect pathologies, find the genes or the pathogen responsible for a disease, and also find the best treatment. The most recent generation of microarray allows scientists to readily perform DNA analysis, providing the ability to analyse complete genomes in a single experiment. The main advantages of microarrays technology are:
- High throughput
- Multiple specimen screen
- Low cost
- Multiple uses
- Reliable results
Although at the beginning, microarray technology has been used as a research technology, now it is transforming in an essential tool for prognosis and diagnostic applications. Furthermore, using array analysis, the expression profiles of normal and tumor tissues, treated and untreated cell cultures, healthy and diseased tissue, developmental stages of an organism or tissue, can be compared, and the range of microarray applications is really enormous.
Biotools B&M Labs., S.A. presents you the Proteogene-Microarray Line, a portfolio of biochip-based high-throughput technology platforms and their applications. The spectrum of our products includes biochips and their related instrumentation, controls, software and databases.
In 2007, Biotools began a partnership with CapitalBio Corporation, a leading life science company based in Beijing, P.R. China that produces biochips, and offers products and services to the scientific community. Most of CapitalBio’s proprietary products will be introduced to the Spanish market through this partnership with Biotools.
CapitalBio Corporation provides a comprehensive product range to a wide spectrum of users. These products include biochips and related instrumentation, software and databases, and reagents and consumables for applications in drug development, clinical diagnostics, and biosafety testing to address numerous human health issues.
CapitalBio is ISO 9001 and ISO 13485 certified. In addition, CapitalBio’s products are certified with the appropriate CE Certificates and TUV/GS Certificates in Europe and the USA. The Company has established strategic partnerships with an international network of businesses in the US and UK as well as distributors and dealers worldwide. CapitalBio’s products have entered the clinical and research markets in 13 countries.
Innovation drives CapitalBio’s continuous growth in the Life Science technology field. CapitalBio has also developed various cutting-edge biochips utilising microfluidic technology, microprocessor technology and bio-electro-magnetic technology. Until now, CapitalBio has filed over 100 patent applications, the majority of which have already been issued. CapitalBio has a strong reputation among researchers for its biochip related instruments. In addition, its products have been awarded numerous prizes. CapitalBio won first place of the top 50 fast-growing high-tech companies in the “Deloitte Technology Fast 50 China 2006”. In 2007, CapitalBio won the Second Prize of the prestigious National Awards for Technological Innovation.
CapitalBio Patents and Publications:
- Over 100 patent applications, of which 12 patents from the US, 45 from mainland China, 2 from Hong Kong, 2 from Australia and 1 each from Taiwan, Japan and Europe have been issued
- Over 60 research papers in major international journals
- 6 English and 5 Chinese technical books
CapitalBio’s products and machinery have won their respect in the West and they have been supported by the journals Nature and Science.
Biotools B&M Labs., S.A. is actively researching innovative "complete solution" technologies for biomedical research applications, as well as the possibility of expanding these technologies across many disciplines. We constantly establish partnerships and close relationships with academic and research institutions, as well as biotechnological and pharmaceutical companies with the purpose and commitment of expanding the Microarray Line according to market expectations. The Biotools research and development team, together with our partners, has been working to develop products and applications for bio-safety tests, clinical diagnostics, drug screening, drug discovery and biomedical research.
- SOFTWARES and DATABASE
- ARRAY SPECIFIC EQUIPMENT
- ADDITIONAL EQUIPMENT